Category: Heel Pharmacological Index

Zingiber-Injeel
D 10, D 30, D 200 0.367 ml each.

Meteorism, flatulence; bronchial asthma, particularly nocturnal.

Vesica urinaria suis-Injeel and forte
(bladder)

Disturbances of the renal excretion, oxaluria, uremia, nephrolithiasis, cystopyelitis, hydronephrosis, glomerulonephritis and nephrosis, papillomas of the bladder, vesical tenesmus, prostatic adenoma; exerts a channelling and stimulating action on the renal excretion and the overall detoxication, and should therefore be interposed for numerous chronic diseases (with Colon suis-Injeel, Hepar suis-Injeel, Vesica fellea suis-Injeel).

Crocus-Injeel
D 12, D 30, D 200 0.367 ml each.
Crocus-Injeel forte
D 4, D 12, D 30, D 200 0.275 ml each.

Burning of the eyes; metrorrhagia (worsened by the slightest movement); hysteria, chorea minor.

Gamma-Globulin-Injeel
D 10, D 30, D 200 0.367 ml each.

g-Gamma-globulin is the carrier of the antibody function. The practical application of gamma-globulin consists of the prophylactic and therapeutic control (passive immunization) of infectious diseases, including, in particular, viral diseases, the causal agents of which still cannot normally be isolated, e.g. herpes zoster, varicella, measles, mumps, infectious mononucleosis, poliomyelitis, hepatitis. The administration of fairly small doses of gamma-globulins gives rise to a diminished clinical picture with longterm immunity, which, from the biological point of view, is extremely desirable.

From clinical and in vitro experiments (Dr. med. H. Veith, chief physician:

Nachweis des sogenannten Schärfungseffektes von homöopathisiertem Gammaglobulin in vivo und in vitro (Evidence of the enhancing effect of homoeopathically adjusted gamma-globulin in vivo and in vitro); Biologische Medizin, Vol. 4, No. 6 1975, pp. 444-448. Dr. Schedel’s Clinic, Scientific Institute for Protogerontology, 8391 Kellberg), it has been possible to establish that this enhancing effect is also observed when a substance formed by the body itself, e.g. gamma-globulin, is administered in homoeopathically adjusted form.

The results in detail:

(a) The i.v. administration of Gamma-Globulin-Injeel within 14 days 5 times in succession to 50 patients with corresponding Indications (weakness of the defensive mechanism against infection) led to no alteration in the electrophoresis of the plasma protein, while, in particular, the gamma-globulin fractions showed no definite fluctuations. There were, therefore, no circumstances to be attributed eventually to the law of mass action.

(b) Although Gamma-Globulin-Injeel effects no alteration to the percentage of human globulin in the organism, in all patients quite a considerable reduction in their propensity to infection could be observed. It was possible to confirm this objectively on the basis of two series of tests on in-patients during two epidemics of colds in February and April 1975, when an untreated control group of 105 + 94 patients (= 199 cases) was compared with a group of 73 + 84 patients (= 157 cases), each of whom had been inoculated intradermally once with Gamma-Globulin-Injeel (by needleless injector Dermo-Jet).

(c) From immunological research the fact is known that sera containing immune globulin possess haemolytic properties. Since also in the potentiated form, gamma-globulin still contains immune globulin, the possibility was tested experimentally of determining the influence of the addition of homoeopathically adjusted gamma-globulin in the D 10 potency on the haemolytic effect of immune globulin. It was found that through the addition of gamma-globulin in D 10, a 30% higher haemolysis was recorded than when gamma-globulin alone was administered in the traditional dosage (50 corresponding in vitro experiments, the photometer deflection for the latter experiment being on average 11 and for the former, on average 16).

The haemolytic effect of immune globulin can, therefore, be considerably intensified through the addition of homoeopathically adjusted gamma-globulin in the D 10 potency, which corresponds to an enhancing effect and, therefore, could be established also in vitro and not merely clinically and experimentally (see above and under Vitamin B12-Injeel.)

Baryum carbonicum-Injeel
D 12, D 30, D 200 0.367 ml each.
Baryum carbonicum-Injeel forte
D 6, D 12, D 30, D 200 0.275 ml each.

Especially for children with tonsillar hypertrophy and in geriatrics; children who are disinterested, anxious; lymphatism, scrofulous glandular swellings, sensitivity to cold, arteriosclerosis, tinnitus aurium, dysacousis, vertigo, poor memory, insomnia, lipomas (particularly in the neck).

Glandula suprarenalis suis-Injeel and forte
(mixture of the two suprarenal glands)

Adynamia, bronchial asthma, conditions of exhaustion, Addison’s disease and other symptoms of exhausted suprarenal glands; primary chronic polyarthritis, hypotonia, vagotonia, neurodermatitis, rhagades, colitis mucosa, spasmophilia; after burns; geriatric remedy.

Cerebrum suis-Injeel and forte
(cerebrum)

Conditions of mental exhaustion and disturbances in development; functional weakness and circulatory disturbances of the brain, progressive paralysis (after-treatment), paraplegia, arteriosclerotic dementia, encephalomalacia.

Medulla oblongata suis-Injeel and forte
(medulla)

Paralysis agitans, progressive bulbar palsy, polyneuritis, multiple sclerosis, amyotrophic lateral sclerosis, tabes dorsales, spinal paralysis, hypotonia, chorea minor, disturbances in the vegetative centers, including, for example, bronchial asthma.

Arnica-Injeel S
D 12, D 30, D 200 0.367 ml each.
Arnica-Injeel forte S
D 4, D 12, D 30, D 200 0.275 ml each.

To stimulate the healing of wounds; fractures, dislocations, contusions, haematomas, myocardial weakness, apoplexia cerebri, neuralgia, myalgia, worsening of condition through contact and movement, feeling of weakness.

Contraindications (Injeel forte)

Hypersensitivity to members of the Compositae family.

Tonsilla suis-Injeel and forte
(tonsil)

Tonsillar hypertrophy, chronic tonsillitis, lymphatism, scrofulosis, exudative diathesis; also to be administered experimentally in lymphogranulomatosis and reticulosis.